The Study of the Possible Program-related Factors Contributing to Drug Resistance in Tuberculosis Patients

Document Type : Original Article


1 Department of Respiratory Medicine, Gandhi Medical College, Bhopal, Madhya Pradesh, India

2 Department of Otolaryngology, Netaji Subhash Chandra Bose Medical College Jabalpur, Bhopal, Madhya Pradesh, India

3 Department of General Medicine, Gandhi Medical College, Bhopal, Madhya Pradesh, India


Background and aim: The prolonged duration of treatment, the need for multiple drugs, adverse drug reactions, and socioeconomic factors are the main reasons for non-adherence to treatment for tuberculosis which can lead to drug resistance, risk of transmission, and death. Understanding the factors for drug resistance in tuberculosis (TB) patients is essential. This study assesses the factors contributing to drug resistance in tuberculosis patients.
Material and methods: This is a cross-sectional study done on 198 patients diagnosed with drug-resistance tuberculosis (DRTB) at the Department of Respiratory Medicine, Gandhi Medical College, Bhopal were included.
Results: In this study, 71.7% of study participants were male; the majority of patients were of age group 30-40 years (36.4%) and of BMI<18.5 (59.6%), and 37.9% were educated up to middle school. In this study, inadequate training of health care workers, no direct benefit transfer to the patient, and improper counseling were found statistically significant (p value<0.05) as possible factors leading to DRTB. In contrast, the increased distance of residence from the drug distribution center and the non-availability of drugs had no significant correlation (p-value>0.05).
Conclusions: The study concludes that the above possible factors contributing to drug resistance should be considered in high-risk group TB patients. It can be done through proper training of health care workers, transferring the direct benefits entitled to the TB patients on time, and ensuring the availability of drugs around the year.


Main Subjects

[1] Chakraborty AK. Epidemiology of tuberculosis: current status in India. Indian journal of medical research. 2004;120(4):248-76.
[2] Udwadia ZF, Mehra C. Tuberculosis in India. BMJ. 2015;350.
[3] Law S. Exploring TB patient journeys and the emergence of MDR-TB in India and South Africa: A multi-methods study. McGill University (Canada); 2019;28248042.
[4] Satyanarayana S, Nair SA, Chadha SS, Shivashankar R, Sharma G, Yadav S, et al. From where are tuberculosis patients accessing treatment in India? Results from a cross-sectional community based survey of 30 districts. PloS one. 2011;6(9):e24160.
[5] Chauhan LS, Arora VK. Management of pediatric tuberculosis under the Revised National Tuberculosis Control Program (RNTCP). Indian Pediatr. 2004;41(9):901-5.
[6] Yang C, Luo T, Shen X, Wu J, Gan M, Xu P, et al. Transmission of multidrug-resistant Mycobacterium tuberculosis in Shanghai, China: a retrospective observational study using whole-genome sequencing and epidemiological investigation. The Lancet Infectious Diseases. 2017;17(3):275-84.
[7] Seung KJ, Keshavjee S, Rich ML. Cold Spring Harbor Perspect. Med. 2015;5(9):a017863.
[8] Hirpa S, Medhin G, Girma B, Melese M, Mekonen A, Suarez P, et al. Determinants of multidrug-resistant tuberculosis in patients who underwent first-line treatment in Addis Ababa: a case control study. BMC Public Health. 2013;13:1-9.
[9] Fikre A, Tewelde T, Shaweno T. Determinants of multi-drug resistant tuberculosis among tuberculosis patients in Southern Ethiopia: a case control study. Journal of Medical Bacteriology. 2019;8(1-2):1-12.
[10] Admassu F, Abera E, Gizachew A, Sedoro T, Gari T. Risk factors of multidrug resistant tuberculosis among patients with tuberculosis at selected multidrug resistance treatment initiative centres in southernEthiopia: a case-control study. BMJ open. 2023;13(1):e061836.
[11] Oga-Omenka C, Tseja-Akinrin A, Sen P, Mac-Seing M, Agbaje A, Menzies D, et al. Factors influencing diagnosis and treatment initiation for multidrug-resistant/rifampicin-resistant tuberculosis in six sub-Saharan African countries: a mixed-methods systematic review. BMJ global health. 2020;5(7):e002280.
 [12] Chowdhury K, Ahmad R, Sinha S, Dutta S, Haque M. Multidrug-Resistant TB (MDR-TB) and Extensively Drug-Resistant TB (XDR-TB) Among Children: Where We Stand Now. Cureus. 2023;15(2):e35154.